Characterizing the interaction modes of PAR4 receptor with agonist and antagonist by molecular simulation approach

被引:0
|
作者
Lu, Nan [1 ,2 ]
Meng, Fancui [2 ]
Yuan, Jing [2 ]
Liu, Lei [2 ]
Wang, Yanshi [2 ]
Li, Lingjun [2 ]
Zhao, Tong [2 ]
Xu, Weiren [2 ]
Tang, Lida [2 ]
Xu, Youjun [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Liaoning, Peoples R China
[2] Tianjin Inst Pharmaceut Res, Tianjin Key Lab Mol Design & Drug Discovery, Tianjin 300193, Peoples R China
来源
JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY | 2019年 / 18卷 / 02期
关键词
PAR4; molecular docking; molecular dynamics; agonist; antagonist; PLATELET ACTIVATION; PROTEIN-STRUCTURE; IONIC LOCK; GENERATION; MECHANISM; EFFICIENT; PEPTIDE; BINDING;
D O I
10.1142/S0219633619500081
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Protease-activated receptor 4 (PAR4) is a promising target for antiplatelet therapy. In this study, homology modeling and molecular docking methods were used to investigate the binding modes of PAR4 agonists and antagonists. The outcomes show that agonists have good docking scores, and they also form more hydrogen bonds with PAR4 than antagonists. To reveal the different conformational changes caused by agonist and antagonist, molecular dynamic simulations were carried out on three selected PAR4 systems. Simulation results show that PAR4 activation involves breaking interactions of 3-7 lock switch (Try157 and Tyr322) and ionic lock switch (Arg188 and Asp173), and formation of transmission switch among Tyr161, Asn300 and Phe296. In addition, principal component analysis (PCA) indicates that the major change for agonist bound system takes place in the intracellular region while that for antagonist bound system is in the extracellular region. The binding free energy of BMS-986120 is much lower than AYPGKF, suggesting high affinity of antagonist. Moreover, the electronegative aspartic residues Asp230 and Asp235 at ECL2 are important for PAR4 binding to agonist. Clarifying the PAR4 structural characteristics may be helpful to understand the activation mechanism, giving insights into the molecular design and discovery of novel potential PAR4 antagonists in the future.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4)
    Thibeault, Pierre E.
    LeSarge, Jordan C.
    Arends, D'Arcy
    Fernandes, Michaela
    Chidiac, Peter
    Stathopulos, Peter B.
    Luyt, Leonard G.
    Ramachandran, Rithwik
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (08) : 2520 - 2540
  • [22] Protease-activated receptor PAR4 drives cardiac inflammatin in diabetes
    Fender, A.
    Stolte, S.
    Leineweber, K.
    Kamler, M.
    Dobrev, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 13 - 13
  • [23] Direct neuronal protection by the protease-activated receptor PAR4 antagonist ML354 after experimental stroke in mice
    Fleischer, M.
    Szepanowsk, R.
    Pesara, V.
    Bihorac, J. S.
    Oehler, B.
    Dobrev, D.
    Kleinschnftz, C.
    Fender, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S69 - S69
  • [24] Thrombin receptor PAR4 coordinates inflammatory stress platforms in diabetic atria
    Mittendorf, C.
    Poertner, J.
    Kassler, L.
    Puzicha, T.
    Kamler, M.
    Dobrev, D.
    Fender, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (SUPPL 1) : S6 - S6
  • [25] Direct neuronal protection by the protease-activated receptor PAR4 antagonist ML354 after experimental stroke in mice
    Fleischer, Michael
    Szepanowski, Rebecca D.
    Pesara, Valeria
    Bihorac, Julia Sophie
    Oehler, Beatrice
    Dobrev, Dobromir
    Kleinschnitz, Christoph
    Fender, Anke C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2024, 181 (18) : 3364 - 3379
  • [26] Molecular Determinants of Selective Agonist and Antagonist Binding to the Histamine H4 Receptor
    Istyastono, Enade P.
    de Graaf, Chris
    de Esch, Iwan J. P.
    Leurs, Rob
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (06) : 661 - 679
  • [27] DIFFERENTIAL INTERACTION OF THE OPIOID RECEPTOR WITH AGONIST AND ANTAGONIST MORPHINAN DERIVATIVES
    LEMAIRE, S
    BELLEAU, B
    FASEB JOURNAL, 1988, 2 (05): : A1391 - A1391
  • [28] AGONIST-ANTAGONIST INTERACTION AT CHOLINERGIC RECEPTOR OF DENERVATED DIAPHRAGM
    FREEMAN, SE
    TURNER, RJ
    AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE, 1972, 50 (FEB): : 21 - &
  • [29] Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides
    Hollenberg, MD
    Saifeddine, M
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (05) : 439 - 442
  • [30] Novel Role for Proteinase-activated Receptor 2 (PAR2) in Membrane Trafficking of Proteinase-activated Receptor 4 (PAR4)
    Cunningham, Margaret R.
    McIntosh, Kathryn A.
    Pediani, John D.
    Robben, Joris
    Cooke, Alexandra E.
    Nilsson, Mary
    Gould, Gwyn W.
    Mundell, Stuart
    Milligan, Graeme
    Plevin, Robin
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (20) : 16656 - 16669